Cargando…
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (QTc) and (ii) to examine the relationship between plasma talazoparib concentration and QTc. In this open-label...
Autores principales: | Hoffman, Justin, Chakrabarti, Jayeta, Plotka, Anna, Milillo Naraine, Adriana, Kanamori, David, Moroose, Rebecca, Nguyen, Linh, Wang, Diane, Wainberg, Zev A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485310/ https://www.ncbi.nlm.nih.gov/pubmed/30875341 http://dx.doi.org/10.1097/CAD.0000000000000772 |
Ejemplares similares
-
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022) -
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
por: Durairaj, Chandrasekar, et al.
Publicado: (2021) -
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
por: Durairaj, Chandrasekar, et al.
Publicado: (2018) -
Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours
por: Elmeliegy, Mohamed, et al.
Publicado: (2020) -
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)